Produção Nacional
Revisado por pares
Cost‐effectiveness of an exercise‐based cardiovascular rehabilitation program in patients with chronic Chagas cardiomyopathy in Brazil: An analysis from the PEACH study
2022; Wiley; Volume: 27; Issue: 7 Linguagem: Inglês
10.1111/tmi.13784
ISSN1365-3156
AutoresValeria Alencar Linhares Simões, Fernanda de Souza Nogueira Sardinha Mendes, Alexandre Monken Avellar, Gilberto Marcelo Sperandio da Silva, Fernanda Martins Carneiro, Paula Simplício da Silva, Flavia Mazzoli‐Rocha, Rudson Santos da Silva, Marcelo Carvalho Vieira, Celson Júnio do Nascimento Costa, Andréa Silvestre de Sousa, Cláudia Maria Valete Rosalino, Patrícia Fernandes da Silva Nobre, Marcelo Teixeira de Holanda, Henrique Silveira Costa, Roberto Magalhães Saraiva, Alejandro Marcel Hasslocher‐Moreno, Rodolfo Castro, Mauro Felippe Felix Mediano,
Tópico(s)Cardiomyopathy and Myosin Studies
ResumoThe present study aimed to perform a cost-effectiveness analysis of an exercise-based cardiovascular rehabilitation (CR) program in patients with chronic Chagas cardiomyopathy (CCC).Cost-effectiveness analysis alongside a randomised clinical trial evaluating the effects of a 6-month exercise-based CR program. The intervention group underwent 3 weekly exercise sessions. The variation of peak oxygen consumption (VO2peak ) was used as a measurement of clinical outcome. Cost information from all healthcare expenses (examinations, healthcare visits, medication and hospitalisation) were obtained from the medical records in Brazilian reais (R$) and transformed into dollars using the purchasing power parity ($PPP). The longitudinal costs variation was evaluated through linear mixed models, represented by β coefficient, adjusted for the baseline values of the dependent variable. The cost-effectiveness evaluation was determined through an incremental cost-effectiveness ratio using the HEABS package (Stata 15.0).The intervention group presented higher costs with healthcare visits (β = +3317.3; p < 0.001), hospitalisation (β = +2810.4; p = 0.02) and total cost (β = +6407.9; p < 0.001) after 3 months of follow-up. Costs related to healthcare visits (β = +2455.8; p < 0.001) and total cost (β = +4711.4; p < 0.001) remained higher in the intervention group after 6 months. The CR program showed an incremental cost-effectiveness ratio (ICER) of $PPP 1874.3 for each increase of 1.0 ml kg-1 min-1 of VO2peak .The CR program can be considered a cost-effective alternative and should be included as an intervention strategy in the care of patients with CCC.
Referência(s)